Filings

Below are the latest summaries of filings submitted to SEC.

Q2 2024 SEC Filing Analysis: Key Insights from the Latest 10-Q Submission

Tonix Pharmaceuticals Q2 2024: Navigating Challenges and Opportunities

Sunshine Biopharma's Q2 2024: A Bright Spot Amid Challenges

Analyzing Flowers Foods' Q2 2024 10-Q: Resilience Amid Challenges

KKR Financials: A Deep Dive into Q2 2024 Results

Enterprise Products Partners L.P. Q2 2024: Strong Revenue Growth Amid Rising Costs